Astex Announces Exclusive Research Collaboration and License Agreement with Genentech for Breast Cancer Therapy Program
Michelle Jones, president of Astex Pharmaceuticals, said, “Working together with colleagues from Newcastle University, Astex’s fragment-based drug discovery expertise has led to the discovery of a novel and innovative approach to selectively inhibit this key oncology target for breast cancer therapy. Genentech’s focus on embracing innovation, its expertise in oncology and its longstanding dedication to innovation for breast cancer patients makes Genentech an excellent partner for this collaboration. We are delighted to be working together in this important drug discovery alliance with the aim to build on our progress and accelerate compounds into development in a rapidly emerging area of need which, as yet, remains unmet.”
Share:
More News
“This acquisition further strengthens our late-stage oncology pipeline and reflects our continued focus on bringing transformational treatments to people living with cancer,” said David Loew, CEO, Ipsen. “We are excited by the potential of navtemadlin to define a new treatment paradigm for patients with myelofibrosis who have a suboptimal response
“We are pleased to partner with Roche to explore the combination potential of EXP011 and atezolizumab for patients with SCLC and other hard-to-treat solid tumors.” said Lei Fang, Ph.D., Co-Founder, Chairman and Chief Executive Officer, Excalipoint Therapeutics. “This collaboration enables us to evaluate a differentiated immuno-oncology combination strategy to address
Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “For patients with newly diagnosed MCL, chemotherapy is currently the default. MANGROVE demonstrates for the first time that BRUKINSA plus rituximab, a chemotherapy-free regimen, can deliver unprecedented improvements in progression-free survival, potentially redefining the treatment paradigm globally. We believe
“ADCs have become an important part of cancer treatment, but there remains a clear need for new payload mechanisms to overcome resistance and expand their impact for patients,” said Fiona Marshall, President of Biomedical Research at Novartis. “Myricx Bio has developed a promising NMTi payload platform with a differentiated mechanism